Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas

Journal of Neuro-Oncology

Volumn 121, Issue 1, 2015, Pages 53-61

  Ivan, Michael E ^a   Safaee, Michael ^a   Oh, Taemin ^b   Clark, Aaron J ^a   Sun, Matthew Z ^a   Kim, Joseph ^a   Bloch, Orin ^b   Jahangiri, Arman ^a   Phillips, Joanna J ^a   Aghi, Manish K ^a   Parsa, Andrew T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; EGF TM7; EMR2; G protein coupled receptor; Glioblastoma; Isoform

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EMR2 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; ISOPROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY;

ANIMAL; CANCER GRADING; CANCER TRANSPLANTATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE, NUDE; NEOPLASM GRADING; NEOPLASM TRANSPLANTATION; PROTEIN ISOFORMS; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER;

EID: 84921057841     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1606-z     Document Type: Article

References (41)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG et al (2010) TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 9:194
3. Bjarnadottir TK, Geirardsdottir K, Ingemansson M, Mirza MA, Fredriksson R et al (2007) Identification of novel splice variants of Adhesion G protein-coupled receptors. Gene 387:38–48
4. Lin HH, Stacey M, Hamann J, Gordon S, McKnight AJ (2000) Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics 67:188–200
5. Yona S, Lin HH, Dri P, Davies JQ, Hayhoe RP et al (2008) Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J 22:741–751
6. Chang GW, Davies JQ, Stacey M, Yona S, Bowdish DM et al (2007) CD312, the human adhesion-GPCR EMR2, is differentially expressed during differentiation, maturation, and activation of myeloid cells. Biochem Biophys Res Commun 353:133–138
7. Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH et al (2005) Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol 77:112–119
8. Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD et al (2003) The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102:2916–2924
9. Kwakkenbos MJ, Chang GW, Lin HH, Pouwels W, de Jong EC et al (2002) The human EGF-TM7 family member EMR2 is a heterodimeric receptor expressed on myeloid cells. J Leukoc Biol 71:854–862
10. Davies JQ, Lin HH, Stacey M, Yona S, Chang GW et al (2011) Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncol Rep 25:619–627
11. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK (2013) beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 73:3145–3154
12. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL et al (2013) Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:1773–1783
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404
14. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110
15. Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB et al (2012) Integrative subtype discovery in glioblastoma using iCluster. PLoS ONE 7:e35236
16. Lino MM, Merlo A (2011) PI3 Kinase signaling in glioblastoma. J Neurooncol 103:417–427
17. Tso CL, Shintaku P, Chen J, Liu Q, Liu J et al (2006) Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 4:607–619
18. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206
19. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787
20. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233–242
21. DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S et al (2012) Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18:2930–2942
22. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383–389
23. Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E et al (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 82:77–82
24. Pope WB, Xia Q, Paton VE, Das A, Hambleton J et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432–437
25. Vidal M, Di Cosimo S, Torrejon D et al (2011) Survival outcome with bevacizumab: activation of the phosphatidylinositol-3 kinase (PI3K) pathway due to PIK3CA Mutations or PTEN loss makes a difference. Cancer Res 71: Abstract nr P5-13-01
26. Aust G, Hamann J, Schilling N, Wobus M (2003) Detection of alternatively spliced EMR2 mRNAs in colorectal tumor cell lines but rare expression of the molecule in colorectal adenocarcinomas. Virchows Arch 443:32–37
27. Rutkowski MJ, Sughrue ME, Kane AJ, Kim JM, Bloch O et al (2011) Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. J Neurooncol 105:165–171
28. Kane AJ, Sughrue ME, Rutkowski MJ, Phillips JJ, Parsa AT (2010) EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic target. NeuroReport 21:1018–1022
29. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K et al (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346
30. Toker A, Cantley LC (1997) Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387:673–676
31. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245
32. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657
33. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M et al (1995) Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269:690–693
34. Xie Y, Abel PW, Kirui JK, Deng C, Sharma P et al (2013) Identification of upregulated phosphoinositide 3-kinase gamma as a target to suppress breast cancer cell migration and invasion. Biochem Pharmacol 85:1454–1462
35. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS et al (2010) Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97:33–40
36. Chiu PL, Ng BH, Chang GW, Gordon S, Lin HH (2008) Putative alternative trans-splicing of leukocyte adhesion-GPCR pre-mRNAs generates functional chimeric receptors. FEBS Lett 582:792–798
37. de Groot DM, Vogel G, Dulos J, Teeuwen L, Stebbins K et al (2009) Therapeutic antibody targeting of CD97 in experimental arthritis: the role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2. J Immunol 183:4127–4134
38. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336–30343
39. Hainsworth J (2011) Combination of BKM120 and bevacizumab in refractory solid tumors and relapsed/refractory glioblastoma multiforme. U.S. National Institutes of Health, Bethesda
40. Health USNIo (ed) (2011) GDC-0980 in combination with a fluoropyrimidine, oxaliplatin, and bevacizumab in patients with advanced solid tumors
41. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB et al (2014) Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res 20:404–412